PURPOSE: To determine the efficacy and safety of infliximab in the treatment of refractory posterior @entity1596 . DESIGN: Noncomparative interventional case series. @entity1 : Five @entity1 with posterior @entity1596 were treated: 3 had Beh  et's syndrome, and 2 had @entity23351 . INTERVENTIONS: @entity1 with sight-threatening @entity1596 refractory to other immunosuppressive agents were treated with infliximab. MAIN OUTCOME MEASURES: Intraocular inflammation, by using binocular indirect ophthalmoscopy score, @entity4816 , and visual acuity. Adverse effects of infliximab were documented. RESULTS: Within 2 weeks of the first infusion of infliximab, 4 of 5 @entity1 showed marked improvement in vitreous haze and visual acuity. By the 6-month follow-up, the same four @entity1 had achieved remission of posterior @entity1596 and had successfully withdrawn all other immunosuppressive therapy. Further infusions of infliximab were required in 3 @entity1 . One @entity1 developed @entity24181 , which responded to antituberculous treatment. CONCLUSIONS: Infliximab is effective in the treatment of sight-threatening refractory posterior @entity1596 . However, @entity1 should be thoroughly screened for @entity378 before treatment and followed up closely during and after therapy with infliximab.

Infliximab in the treatment of refractory posterior XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PARTICIPANTS'] @entity1596 :: ('MESH:D014605', 'Disease') :: ['uveitis'] @entity23351 :: ('MESH:D015866', 'Disease') :: ['idiopathic posterior uveitis'] @entity24181 :: ('MESH:D014392', 'Disease') :: ['ocular and systemic tuberculosis'] @entity378 :: ('MESH:D014376', 'Disease') :: ['tuberculosis'] @entity4816 :: ('MESH:D031300', 'Disease') :: ['retinal vasculitis']
@entity1596 :: (MESH:D014605,Disease) :: ['uveitis']
